Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Oncology Target Equipment Supplied In Europe
6 equipment items found
Manufactured by:Tempus based inChicago, ILLINOIS (USA)
Targeted panel designed to detect actionable oncological targets in plasma. ...
Manufactured by:Precirix based inBrussels, BELGIUM
Our lead product candidate, CAM-H2, consists of an HER2-targeting single-domain antibody linked to iodine-131. This targeted radioligand therapy is being developed for the treatment of patients with metastatic HER2-positive cancer indications, such as breast and gastric adenocarcinoma. In addition to the company’s lead program, two product candidates for ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
Orion’s platform and science unlocks the therapeutic potential of GPCR targets across a broad range of medical needs. Our approach allows us to focus our discovery and development efforts across peptide and protein GPCR subfamilies, generating a diversified pipeline of potential first-in-class/best-in-class antagonist and agonist therapies against high-value ...
by:Sibylla Biotech S.p.A. based inVerona, ITALY
We are currently working on the hit-to-lead process for KRAS and Cyclin D1 (CCND1) proteins in the biology ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the entire GPCR family, and many valuable receptors remain undrugged. In particular, GPCRs whose natural ligands are large peptides or small proteins are ...
Manufactured by:Mablink Bioscience based inLyon, FRANCE
Antibody–drug conjugates (ADCs) are a unique class of targeted immuno-oncology therapeutics that combine the tumor-targeting selectivity, stability, and favorable pharmacokinetic profile of monoclonal antibodies, with the potent antitumor activity of cytotoxic drugs. The ultimate goal of ADCs is to increase the therapeutic index of potent ...